Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related ...
EMERALD-3: Phase III trial of IMFINZI ® (durvalumab) in combination with IMJUDO ® (tremelimumab-actl), with or without lenvatinib, and transarterial chemoembolization (TACE) in patients with ...
Recent research has found that GLP-1 class obesity and diabetes treatments, such as Wegovy and Mounjaro, may improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results